Nerbutix (Flucloxacillin)

Flucloxacillin binds irreversibly to penicillin‑binding proteins on the bacterial cell wall, blocking the transpeptidation step of peptidoglycan synthesis. This prevents cross‑linking of the wall, leading to structural weakness, cell lysis and bacterial death. Its structure resists degradation by penicillinase enzymes, preserving activity against resistant Staphylococcus strains.

The dosage of Nerbutix is individualized by the prescribing clinician based on the type and severity of infection, patient age, weight, renal function and other clinical factors. Healthcare professionals determine the appropriate strength, frequency and duration of therapy in accordance with local guidelines and product labeling.

Safety data for flucloxacillin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians should discuss the risk‑benefit profile with the patient and consider alternative agents if appropriate.

To request Nerbutix, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both flucloxacillin (Nerbutix) and oxacillin belong to the penicillinase‑resistant penicillin class and share a similar spectrum against Staphylococcus aureus. Flucloxacillin is often preferred for oral therapy because of its higher oral bioavailability, whereas oxacillin is typically administered intravenously. Choice depends on infection site, severity, patient tolerance and local resistance patterns.

Nerbutix should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments. Do not use if the packaging is damaged or the tablets appear discoloured.

Nerbutix is formulated for oral administration. The tablets (or other oral dosage form) should be swallowed whole with a full glass of water, preferably on an empty stomach to enhance absorption, unless the prescribing information advises otherwise. Patients should follow the prescriber’s instructions regarding timing and food intake.

The most serious adverse reactions include severe allergic responses such as anaphylaxis, life‑threatening skin conditions like Stevens‑Johnson syndrome or toxic epidermal necrolysis, and Clostridioides difficile‑associated colitis. Prompt medical attention is required if symptoms such as difficulty breathing, widespread rash, blistering, or persistent severe diarrhea develop.

Nerbutix is contraindicated in individuals with a known hypersensitivity to flucloxacillin, other penicillins, or any beta‑lactam antibiotics. Patients with a history of severe allergic reactions to related drugs should avoid this medication. Caution is also advised for patients with severe hepatic impairment, as the drug is metabolised by the liver.